Meriofert

Follicle‑Stimulating Hormone; Luteinising Hormone, the active ingredient in Meriofert, is a gonadotropin presented as an injectable solution for intramuscular or subcutaneous use. It is used to treat infertility caused by anovulation, to support ovarian stimulation in assisted reproductive technologies, and to manage hypogonadotropic hypogonadism.

GNH USA supplies Meriofert as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert is a gonadotropin used in reproductive medicine to stimulate ovarian function.

- Infertility due to anovulation: promotes follicular development and ovulation. - Assisted reproductive technology (e.g., IVF) ovarian stimulation: enhances multiple follicle growth for egg retrieval. - Hypogonadotropic hypogonadism: replaces deficient endogenous FSH and LH to restore normal gonadal activity.

Administration of Meriofert may be associated with a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Injection site pain or erythema: mild discomfort at the injection site. - Abdominal bloating or discomfort: transient gastrointestinal symptoms. - Headache: mild to moderate intensity. - Nausea: occasional mild nausea.

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome (OHSS): potentially severe fluid shift and thromboembolic risk. - Multiple pregnancy: increased risk of twins or higher‑order gestations. - Severe allergic reaction: anaphylaxis, urticaria, or angioedema.

Before prescribing Meriofert, clinicians should consider several precautionary measures to ensure safe use.

- Assess baseline ovarian reserve: evaluate antral follicle count and hormone levels. - Monitor estradiol levels during stimulation: adjust dose to avoid excessive response. - Perform ultrasound monitoring of follicular development: detect early signs of OHSS. - Review concomitant medications: avoid agents that may exacerbate ovarian response. - Contraindications: do not use in patients with known hypersensitivity to gonadotropins or active ovarian cysts. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meriofert can interact with other agents that influence reproductive hormone pathways or coagulation.

Major Interactions (Avoid): - GnRH agonists or antagonists: may alter the intended stimulation protocol. - High‑dose estrogen therapy: can suppress endogenous gonadotropin response. - Anticoagulants: increased risk of bleeding at injection sites.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may require a washout period before initiating therapy. - Thyroid hormone replacement: monitor thyroid function as gonadotropins can affect hormone metabolism. - Diuretics: may mask early signs of OHSS; monitor fluid balance.